Upper gastrointestinal cancers
description
Transcript of Upper gastrointestinal cancers
![Page 1: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/1.jpg)
Upper gastrointestinal cancers
Dr Sue DarbyConsultant Medical Oncologist
Weston Park HospitalSheffield
![Page 2: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/2.jpg)
![Page 3: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/3.jpg)
Introduction
• What’s UGI?
• Terminology
• Treatment intent
• Treatment options
• Clinical trials
![Page 4: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/4.jpg)
What’s upper GI?
• Oesophagus
• GOJ
• Stomach
• (Small bowel)
![Page 5: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/5.jpg)
What sorts of cancers?
• Mainly adenocarcinomas (lower oesophagus downwards)
• Squamous cell carcinomas (usually upper or mid oesophagus)
• Gastrointestinal stromal tumours (GIST)
• Lymphoma
• Metastatic tumours (follicular breast, renal)
![Page 6: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/6.jpg)
Treatment intentions
• Neoadjuvant
• (Downstaging)
• Adjuvant
• Curative
• Palliative
![Page 7: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/7.jpg)
Treatment types
• Chemotherapy
• Radiotherapy
• Chemoradiotherapy
• Biological therapy
• (Brachytherapy)
• (Surgery)
![Page 8: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/8.jpg)
Curative treatments
![Page 9: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/9.jpg)
(Neo)adjuvant chemotherapy
• SqCC– 2 cycles neoadjuvant chemotherapy– 2 drugs – cisplatin and 5 fluorouracil– OEO2 trial – increases 2 year survival from
35% to 45% (surgery vs chemo+surgery)– Surgery 4-6 weeks after chemo
![Page 10: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/10.jpg)
(Neo)adjuvant chemotherapy
• AdenoCa– 3 cycles neoadjuvant and 3 cycles adjuvant
chemotherapy– 3 drugs – epirubicin, cisplatin and
capecitabine– MAGIC trial – increases 5 year survival from
23% to 36.5% (surgery vs chemo+surgery)– Surgery 4-6 weeks after neoadjuvant
chemotherapy
![Page 11: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/11.jpg)
ST03
• ECX +/- biological therapy
• HER2 positive– +/- lapatinib– potentially operable lower oesophageal, GOJ
and gastric adenoca
• HER2 negative– +/- bevacizumab– gastric adenoca only
![Page 12: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/12.jpg)
Side effects
• Benefits outweigh risks (in majority)• GI – nausea, vomiting, diarrhoea, constipation,
mucositis• Skin – hair loss, hand-foot syndrome• Neurotoxicity – peripheral, tinnitus/deafness• Renal toxicity• Fatigue• Haematological – thrombocytopenia, anaemia,
neutropenia (neutropenic sepsis)• Cardiovascular – angina/MI, arrhythmias
![Page 13: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/13.jpg)
Contraindications/Cautions
• Ischaemic heart disease
• Renal disease
• Perfomance status
• Patient choice
![Page 14: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/14.jpg)
Chemoradiotherapy
• SCOPE trial – 2 yr survival >50%• 2 cycles of neoadjuvant cisplatin and capecitabine• 5 weeks of daily radiotherapy concomitantly with a further 2
cycles of capecitabine• Side effects
– odynophagia– fatigue– severe dysphagia (towards end of radiotherapy)– treatment related stricture (late effect) - may require dilatation or stenting
• Advantages over surgery – can treat some surgically untreatable cancers (eg locally invasive)
• Disadvantages – nodal disease/field size
![Page 15: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/15.jpg)
Palliative treatments
![Page 16: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/16.jpg)
Palliative chemotherapy – 1st line
• SqCC– Cisplatin/5FU
• AdenoCa– Oesophagus - EOX – epirubicin, oxaliplatin,
capecitabine – adds few months on average– Gastric/GOJ
• HER2 negative – EOX• HER2 positive – cisplatin, 5FU, trastuzumab
(Herceptin) + maintenance trastuzumab• TOGA trial
![Page 17: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/17.jpg)
REAL2
• ECX/ECF/EOX/EOF• No significant difference in survival between
arms• Around 9-11 months median survival• Trend towards best with EOX• Delivery issues• Led to change in practice from using ECF
(PICC lines, continuous infusional chemo) to EOX (oral 5FU, no PICC)
![Page 18: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/18.jpg)
Palliative chemotherapy – 2nd line
• SqCC – nothing
• AdenoCa – docetaxel– COUGAR trial – adds 2 months on average
• Symptomatic benefit/BSC
• Early phase trials (Leeds)
![Page 19: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/19.jpg)
Palliative radiotherapy
• Symptomatic benefit• If local disease only can offer some local control• Good for:
– Dysphagia– Bleeding– Tumour pain
• Side effects minimal and short-lived – odynophagia, increased dysphagia, fatigue
![Page 20: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/20.jpg)
Clinical trials
• Only way to improve outcomes• What current treatments are based on• Form basis for future (better) treatments• Importance of introducing idea to patients at
early stage• Early referral of patients• Opportunity
– patients– doctors
![Page 21: Upper gastrointestinal cancers](https://reader035.fdocuments.in/reader035/viewer/2022062301/56813b7c550346895da48f09/html5/thumbnails/21.jpg)
Questions?